Sarepta Therapeutics, Inc.
SRPTBiotechnology
$19.23−0.47%As of Oct 29vs prior close
- Market cap
- $2B
- P/E (TTM)
- –
- P/E (FY1)
- 4.4×
- From 52W high
- −21.35%
- EPS (LTM)
- -$1.60
- Revenue (LTM)
- $2B
- Net margin
- -6.93%
- Dividend yield
- 0.00%
Nomior Score
43
Patient ValueSpeculativeBottom 35% of the scored universe
Growth36
Quality65
Value67
Momentum28
Resilience38
Growth
+94.88%revenue a year over 9 fiscal years
YE16 $5.4MLTM $2B
Connections
Revenue to profitQ2 YE26
The net loss was 1% of revenue, wider by 33 pts on a year.
Who owns it
2funds